News Releases

Additional protocol-specified analyses of the AscenD-LB Phase 2a results show that patients without elevated plasma ptau181 levels are more responsive than those with such elevation and have substantial treatment benefits to neflamapimod.

BOSTON , Sept. 5, 2023 /PRNewswire/ --  CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced that the Company's senior management team will present at the H.C. Wainwright 25th Annual Global Investment

Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway

BOSTON, Aug. 14, 2023 /PRNewswire/  --   EIP Pharma Inc.  ("EIP Pharma" or the "Company"), a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, today announced that the first patient has been dosed in the Company's RewinD-LB Phase 2b clinical

BOSTON, Aug. 3, 2023 /PRNewswire/ --  EIP Pharma Inc. , a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company's senior management team will present at the Canaccord Genuity 43 rd  Annual Growth Conference on Wednesday, August

BOSTON, MA – May 11, 2023  – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET.

Structural and functional brain MRI of patients before and after neflamapimod treatment shows increased NbM volume and increased functional dynamic connectivity between NbM and deep grey matter BOSTON, MA – April 3, 2023  –  EIP Pharma Inc. , a clinical stage company focused on developing

Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have

BOSTON, MA, January 18 th , 2022 /PRNewswire/ – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million